Developer docs
API playgroundTry for free, no card

Search company profiles

Medicus Pharma

Full company profile

uuid000028k

Namestring
Medicus Pharma
Legal namestring
Medicus Pharma Ltd.
Company typeenum
Public
Founded yearint
2023
Descriptiontext

Medicus Pharma Ltd. (NASDAQ: MDCX) is a Toronto-based, Canadian-incorporated clinical-stage biotechnology company developing non-systemic therapies for dermatologic and endocrine indications. Its two lead assets are SkinJect, a dissolvable microneedle array (D-MNA) delivering 5-fluorouracil for the treatment of basal cell carcinoma, and Teverelix, a GnRH antagonist targeting advanced prostate cancer, endometriosis, and benign prostatic hyperplasia that was added via the September 2025 acquisition of Antev Ltd. The lead SkinJect program reported positive Phase 2 topline data in March 2026 with 73% clinical clearance in the 200µg cohort, while Teverelix received an FDA Study May Proceed letter in February 2026 to commence a Phase 2b trial in advanced prostate cancer, with Orphan Drug Designation and Rare Pediatric Disease Designation pending.

The company operates a pre-revenue, R&D-driven business model with no marketed products and no recurring customer revenue. Future monetization is expected to come from out-licensing or partnering SkinJect and Teverelix to larger pharmaceutical companies, supplemented by potential milestone and royalty streams. To date, operations have been financed almost entirely by equity, warrant, debenture, and structured-financing transactions — including a $4.93M raise in 2023, $7M in May 2025, an $8M debenture in September 2025, $5.1M and $15.3M ATM-related raises in December 2025, and a $22M structured facility in May 2026 — with FY2025 net losses of $35.4M and Q1 2026 net losses of $9.0M. Headcount sits in the 11–50 range, and the company has disclosed a going-concern doubt and Nasdaq minimum bid price non-compliance in April 2026. Strategic ancillary initiatives include a January 2026 Reliant AI partnership for clinical data analytics, a UK clinical footprint, and a UAE expansion tied to a national genome program, but these remain early-stage and do not yet contribute revenue.

Short descriptiontext

Medicus Pharma is a Toronto-based, clinical-stage biotech developing a dissolvable microneedle 5-FU therapy (SkinJect) for basal cell carcinoma and a GnRH antagonist (Teverelix) for prostate cancer, endometriosis, and BPH, with no current product revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, oncology therapeutics, microneedle drug delivery, GnRH antagonist programs, FDA clinical trials
Product category
Clinical-Stage Biotech Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue (clinical-stage)
TypeLicensing Royalties
Description

Medicus Pharma is a clinical-stage biotech with no approved products; reported FY2025 net loss of $35.4 million and Q1 2026 net loss of $9.0 million. Anticipated future revenue is expected to come from out-licensing of SkinJect and Teverelix assets to established pharmaceutical companies for late-stage development and commercialization.

medicuspharma.com
2Capital markets financing (non-operating)
TypeSubscription Recurring
Description

Company funds operations through capital raises including an Equity Distribution Agreement / ATM program up to $50 million, $22 million structured financing facility, $8 million non-dilutive debenture, warrant inducements, and SEPA facilities. Operations are not yet revenue-generating.

in.investing.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1SkinJect
Description

Portfolio company of Medicus Pharma developing a Doxorubicin Microneedle Array (D-MNA) for non-invasive treatment of basal cell carcinoma and Gorlin Syndrome.

medicuspharma.com
+1 more record
Core offering1 text field

Medicus Pharma is a precision-guided, clinical-stage biotech company that acquires and accelerates the development of novel therapeutic assets through Phase 2 proof-of-concept, then pursues licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization. Its pipeline includes SkinJect (a Doxorubicin Microneedle Array patch for basal cell carcinoma and Gorlin Syndrome) and Teverelix (a long-acting GnRH antagonist for advanced prostate cancer, acute urinary retention, and endometriosis).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase 2 SkinJect 200µg cohort: 73% clinical clearance and 40% histological clearance at Day 57 (90 patients)
+4 more records
Product overview1 text field

Medicus Pharma operates a precision-guided biotech portfolio model: a single parent platform (Medicus Pharma Ltd., NASDAQ: MDCX) that acquires and accelerates clinical-stage therapeutic assets through Phase 2 proof-of-concept before seeking licensing or strategic partnerships for late-stage development and commercialization. The core portfolio currently consists of two therapeutic programs — SkinJect (D-MNA, a doxorubicin microneedle array patch for basal cell carcinoma and Gorlin Syndrome, advanced through subsidiary SkinJect Inc.) and Teverelix (a long-acting GnRH antagonist acquired via Antev Ltd. for advanced prostate cancer, acute urinary retention, and endometriosis). These clinical assets are wrapped by an emerging AI-enabled drug development capability, including an agentic AI-enabled clinical platform and a Reliant AI co-developed clinical data analytics platform for site selection, patient stratification, and enrollment forecasting, intended to compress timelines across the portfolio.

Product and service3 records
1SkinJect (D-MNA: Doxorubicin Microneedle Array)
CategoryClinical-stage therapeutic asset (D-MNA drug-device combination)
Description

Investigational, non-surgical drug-device combination delivering doxorubicin directly into tumors via a dissolvable microneedle array patch for the non-invasive treatment of nodular basal cell carcinoma, including patients with Gorlin Syndrome (NBCCS). Advanced through wholly-owned subsidiary SkinJect Inc.

2Teverelix
CategoryClinical-stage therapeutic asset (long-acting GnRH antagonist)
Description

Long-acting next-generation GnRH antagonist in development for advanced prostate cancer (including a cardiovascular high-risk population), acute urinary retention associated with benign prostatic hyperplasia, and endometriosis. Acquired via the September 2025 acquisition of UK-based Antev Limited.

3PRECISION-E2 (Teverelix Endometriosis Phase 2a)
CategoryClinical program (precision-medicine GnRH antagonist)
Description

Phase 2a genomics-enabled clinical trial program evaluating Teverelix in women with symptomatic endometriosis across multiple UAE sites, integrating the Emirati Genome Program to explore how genetic variation influences response to hormonal therapy.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1UAE Genome Program (Emirati Genome Program)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

Collaboration enabling the PRECISION-E2 Phase 2a genomics-enabled clinical trial evaluating Teverelix in women with symptomatic endometriosis in the UAE. The trial leverages the Emirati Genome Program to explore how genetic variation influences response to hormonal therapy, representing one of the first prospective studies integrating genomic profiling with hormonal modulation in endometriosis.

stocktitan.net
2House Energy & Commerce Committee (US Congress)
Strategic tierCoreTypeOthersAnnounced on2026-04-27
Description

CEO Dr. Raza Bokhari and leadership team met with senior members of the House Energy & Commerce Committee on Capitol Hill (including Chair Brett Guthrie) in collaboration with the Gorlin Syndrome Alliance to advocate for Orphan Drug Designation and Registrational IND approval for SkinJect in Gorlin Syndrome. Engagement targets key committee chairs and caucus co-chairs shaping US rare disease policy.

globenewswire.com
3New to The Street
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-04-07
Description

12-part national media series highlighting SkinJect and Teverelix platforms, broadcast on Bloomberg Television across the US, MENA, and Latin America. Builds on an earlier six-part media series (Feb 2026) to raise Medicus' visibility among investors and healthcare communities.

newswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Collaboration to explore development of Teverelix for endometriosis in the United Arab Emirates. Positioned as part of the broader plan to advance Teverelix as potentially the first long-acting injectable GnRH antagonist for women's health indications.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-03-18
Description

Hosted fireside chat featuring Medicus Pharma discussing positive Phase 2 SkinJect topline results (73% clinical clearance in 200-µg arm). Biotechnology equity research analyst engagement to communicate clinical and corporate developments to investors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Non-binding letter of intent to jointly develop an AI-powered clinical data analytics platform for clinical trial execution. Initial one-year, milestone-based engagement capped at $200,000 focuses on dynamic site selection, patient stratification, and enrollment forecasting for an upcoming Teverelix clinical study planned for 2026. Potential expansion to a larger late-stage study in 2028. Platform integrates Reliant's AI technology with Medicus' clinical, operational, and proprietary datasets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Non-binding Memorandum of Understanding (MoU) with Helix Nanotechnologies referenced in connection with advancing Medicus' therapeutics and microneedle technology programs. Specific scope and financial terms not disclosed in available sources.

8Gorlin Syndrome Alliance
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

Collaboration to pursue a compassionate use / expanded access pathway for SKINJECT in patients with Gorlin Syndrome through the FDA's Expanded Access IND Program. Joint effort to collect real-world safety data to support future regulatory filings and expand clinical trials, while also collaborating on Capitol Hill advocacy for orphan drug designation.

pharmiweb.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical and commercial dermatology company developing topical therapies for skin conditions including basal cell carcinoma (with generic and branded assets). Highly comparable to Medicus given its focus on BCC treatment and recent clinical pipeline activity.

TypeDirect peer
Description

Commercial-stage dermatology company marketing Ameluz and BF-RhodoLED for actinic keratosis and exploring basal cell carcinoma indications. Comparable to Medicus as a US-focused dermatology player targeting non-melanoma skin cancer with a procedural/drug-device approach.

3Sun Pharmaceutical Industries (Levulan/Kerastick)
TypeBroad incumbent
Description

Large global pharmaceutical company with an approved photodynamic therapy (Levulan/kerastick) used in BCC treatment. Relevant comparable as an incumbent offering an established non-surgical BCC modality against which SkinJect would compete or pair.

TypeDirect peer
Description

Developer of Orgovyx (relugolix), an FDA-approved oral GnRH antagonist for advanced prostate cancer. Direct competitor to Teverelix in the long-acting GnRH antagonist category for prostate cancer, with established commercial infrastructure.

TypeDirect peer
Description

Specialty pharmaceutical company with Eligard (leuprolide) and supplying a long-acting injectable GnRH agonist in prostate cancer. Comparable to Medicus in the hormonal prostate cancer therapy space where Teverelix is positioning itself.

TypeEmerging player
Description

Clinical-stage company developing dissolvable microarray patch technology for vaccine and therapeutic delivery. Comparable to Medicus from a microneedle/drug-device delivery platform perspective (relevant to SkinJect D-MNA).

TypeEmerging player
Description

Clinical-stage dermatology therapeutics company developing novel topical and immuno-modulatory therapies for skin diseases including rare dermatologic indications. Comparable to Medicus as a small-cap clinical-stage dermatology biotech pursuing niche indications.

TypeBroad incumbent
Description

Developed patidegib (a hedgehog pathway inhibitor) for Gorlin Syndrome under LEO Pharma. Most direct prior competitor in Gorlin Syndrome BCC treatment, providing historical context for the regulatory and clinical bar Medicus must clear with SkinJect.

TypeEmerging player
Description

Commercial-stage genetic medicines company that leveraged Orphan Drug and Rare Pediatric Disease Designations to commercialize Vyjuvek. Highly comparable as a small-cap biotech that successfully translated rare-disease designations into commercial value, illustrating the regulatory pathway Medicus is pursuing.

TypeOthers
Description

AI-driven clinical data analytics platform partner co-developing Medicus's site selection, patient stratification, and enrollment forecasting capability. Relevant as the technology partner enabling Medicus's 'agentic AI-enabled drug development' narrative.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medicus Pharma

Clinical-Stage Biotech Therapeuticsmedicuspharma.com

Medicus Pharma is a Toronto-based, clinical-stage biotech developing a dissolvable microneedle 5-FU therapy (SkinJect) for basal cell carcinoma and a GnRH antagonist (Teverelix) for prostate cancer, endometriosis, and BPH, with no current product revenue.

What Medicus Pharma does

Medicus Pharma Ltd. (NASDAQ: MDCX) is a Toronto-based, Canadian-incorporated clinical-stage biotechnology company developing non-systemic therapies for dermatologic and endocrine indications. Its two lead assets are SkinJect, a dissolvable microneedle array (D-MNA) delivering 5-fluorouracil for the treatment of basal cell carcinoma, and Teverelix, a GnRH antagonist targeting advanced prostate cancer, endometriosis, and benign prostatic hyperplasia that was added via the September 2025 acquisition of Antev Ltd. The lead SkinJect program reported positive Phase 2 topline data in March 2026 with 73% clinical clearance in the 200µg cohort, while Teverelix received an FDA Study May Proceed letter in February 2026 to commence a Phase 2b trial in advanced prostate cancer, with Orphan Drug Designation and Rare Pediatric Disease Designation pending.

The company operates a pre-revenue, R&D-driven business model with no marketed products and no recurring customer revenue. Future monetization is expected to come from out-licensing or partnering SkinJect and Teverelix to larger pharmaceutical companies, supplemented by potential milestone and royalty streams. To date, operations have been financed almost entirely by equity, warrant, debenture, and structured-financing transactions — including a $4.93M raise in 2023, $7M in May 2025, an $8M debenture in September 2025, $5.1M and $15.3M ATM-related raises in December 2025, and a $22M structured facility in May 2026 — with FY2025 net losses of $35.4M and Q1 2026 net losses of $9.0M. Headcount sits in the 11–50 range, and the company has disclosed a going-concern doubt and Nasdaq minimum bid price non-compliance in April 2026. Strategic ancillary initiatives include a January 2026 Reliant AI partnership for clinical data analytics, a UK clinical footprint, and a UAE expansion tied to a national genome program, but these remain early-stage and do not yet contribute revenue.

Medicus Pharma firmographics

Firmographics
Name
Medicus Pharma
Legal name
Medicus Pharma Ltd.
Website
https://medicuspharma.com
Company type
Public
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Medicus Pharma is a Toronto-based, clinical-stage biotech developing a dissolvable microneedle 5-FU therapy (SkinJect) for basal cell carcinoma and a GnRH antagonist (Teverelix) for prostate cancer, endometriosis, and BPH, with no current product revenue.
Ownership category
akta.pro rank

Where Medicus Pharma is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Medicus Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Pre-revenue (clinical-stage): Medicus Pharma is a clinical-stage biotech with no approved products; reported FY2025 net loss of $35.4 million and Q1 2026 net loss of $9.0 million. Anticipated future revenue is expected to come from out-licensing of SkinJect and Teverelix assets to established pharmaceutical companies for late-stage development and commercialization.
  2. Capital markets financing (non-operating): Company funds operations through capital raises including an Equity Distribution Agreement / ATM program up to $50 million, $22 million structured financing facility, $8 million non-dilutive debenture, warrant inducements, and SEPA facilities. Operations are not yet revenue-generating.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Medicus Pharma product offering

Product offering

Core offering

Medicus Pharma is a precision-guided, clinical-stage biotech company that acquires and accelerates the development of novel therapeutic assets through Phase 2 proof-of-concept, then pursues licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization. Its pipeline includes SkinJect (a Doxorubicin Microneedle Array patch for basal cell carcinoma and Gorlin Syndrome) and Teverelix (a long-acting GnRH antagonist for advanced prostate cancer, acute urinary retention, and endometriosis).

Product overview

Medicus Pharma operates a precision-guided biotech portfolio model: a single parent platform (Medicus Pharma Ltd., NASDAQ: MDCX) that acquires and accelerates clinical-stage therapeutic assets through Phase 2 proof-of-concept before seeking licensing or strategic partnerships for late-stage development and commercialization. The core portfolio currently consists of two therapeutic programs — SkinJect (D-MNA, a doxorubicin microneedle array patch for basal cell carcinoma and Gorlin Syndrome, advanced through subsidiary SkinJect Inc.) and Teverelix (a long-acting GnRH antagonist acquired via Antev Ltd. for advanced prostate cancer, acute urinary retention, and endometriosis). These clinical assets are wrapped by an emerging AI-enabled drug development capability, including an agentic AI-enabled clinical platform and a Reliant AI co-developed clinical data analytics platform for site selection, patient stratification, and enrollment forecasting, intended to compress timelines across the portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • SkinJect: Portfolio company of Medicus Pharma developing a Doxorubicin Microneedle Array (D-MNA) for non-invasive treatment of basal cell carcinoma and Gorlin Syndrome.
  • Antev Ltd

Products and services

  • SkinJect (D-MNA: Doxorubicin Microneedle Array) Investigational, non-surgical drug-device combination delivering doxorubicin directly into tumors via a dissolvable microneedle array patch for the non-invasive treatment of nodular basal cell carcinoma, including patients with Gorlin Syndrome (NBCCS). Advanced through wholly-owned subsidiary SkinJect Inc.
  • Teverelix Long-acting next-generation GnRH antagonist in development for advanced prostate cancer (including a cardiovascular high-risk population), acute urinary retention associated with benign prostatic hyperplasia, and endometriosis. Acquired via the September 2025 acquisition of UK-based Antev Limited.
  • PRECISION-E2 (Teverelix Endometriosis Phase 2a) Phase 2a genomics-enabled clinical trial program evaluating Teverelix in women with symptomatic endometriosis across multiple UAE sites, integrating the Emirati Genome Program to explore how genetic variation influences response to hormonal therapy.

Quantifiable outcome

  • Phase 2 SkinJect 200µg cohort: 73% clinical clearance and 40% histological clearance at Day 57 (90 patients)
  • +4 more outcomes

Companies that use Medicus Pharma

Customer profile

Segments5 records

Ideal customer profiles4 records

Medicus Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Medicus Pharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • UAE Genome Program (Emirati Genome Program)coreStrategic or Co-development Partner · 11 June 2026Collaboration enabling the PRECISION-E2 Phase 2a genomics-enabled clinical trial evaluating Teverelix in women with symptomatic endometriosis in the UAE. The trial leverages the Emirati Genome Program to explore how genetic variation influences response to hormonal therapy, representing one of the first prospective studies integrating genomic profiling with hormonal modulation in endometriosis.
  • House Energy & Commerce Committee (US Congress)coreOthers · 27 April 2026CEO Dr. Raza Bokhari and leadership team met with senior members of the House Energy & Commerce Committee on Capitol Hill (including Chair Brett Guthrie) in collaboration with the Gorlin Syndrome Alliance to advocate for Orphan Drug Designation and Registrational IND approval for SkinJect in Gorlin Syndrome. Engagement targets key committee chairs and caucus co-chairs shaping US rare disease policy.
  • New to The StreetcoreGTM or Marketing Partner · 7 April 202612-part national media series highlighting SkinJect and Teverelix platforms, broadcast on Bloomberg Television across the US, MENA, and Latin America. Builds on an earlier six-part media series (Feb 2026) to raise Medicus' visibility among investors and healthcare communities.
  • Omics LabsminorStrategic or Co-development Partner · 1 April 2026Collaboration to explore development of Teverelix for endometriosis in the United Arab Emirates. Positioned as part of the broader plan to advance Teverelix as potentially the first long-acting injectable GnRH antagonist for women's health indications.
  • Brookline Capital MarketsminorGTM or Marketing Partner · 18 March 2026Hosted fireside chat featuring Medicus Pharma discussing positive Phase 2 SkinJect topline results (73% clinical clearance in 200-µg arm). Biotechnology equity research analyst engagement to communicate clinical and corporate developments to investors.
  • Reliant AI Inc.coreStrategic or Co-development Partner · 22 December 2025Non-binding letter of intent to jointly develop an AI-powered clinical data analytics platform for clinical trial execution. Initial one-year, milestone-based engagement capped at $200,000 focuses on dynamic site selection, patient stratification, and enrollment forecasting for an upcoming Teverelix clinical study planned for 2026. Potential expansion to a larger late-stage study in 2028. Platform integrates Reliant's AI technology with Medicus' clinical, operational, and proprietary datasets.
  • Helix NanotechnologiescoreStrategic or Co-development Partner · 1 December 2025Non-binding Memorandum of Understanding (MoU) with Helix Nanotechnologies referenced in connection with advancing Medicus' therapeutics and microneedle technology programs. Specific scope and financial terms not disclosed in available sources.
  • Gorlin Syndrome AlliancecoreStrategic or Co-development Partner · 29 October 2025Collaboration to pursue a compassionate use / expanded access pathway for SKINJECT in patients with Gorlin Syndrome through the FDA's Expanded Access IND Program. Joint effort to collect real-world safety data to support future regulatory filings and expand clinical trials, while also collaborating on Capitol Hill advocacy for orphan drug designation.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Medicus Pharma competitors and assessment

Company assessment

Direct peers

  • Sol-Gel Technologies: Clinical and commercial dermatology company developing topical therapies for skin conditions including basal cell carcinoma (with generic and branded assets). Highly comparable to Medicus given its focus on BCC treatment and recent clinical pipeline activity.
  • Biofrontera Inc. Commercial-stage dermatology company marketing Ameluz and BF-RhodoLED for actinic keratosis and exploring basal cell carcinoma indications. Comparable to Medicus as a US-focused dermatology player targeting non-melanoma skin cancer with a procedural/drug-device approach.
  • Myovant Sciences (Sumitomo Pharma / Pfizer): Developer of Orgovyx (relugolix), an FDA-approved oral GnRH antagonist for advanced prostate cancer. Direct competitor to Teverelix in the long-acting GnRH antagonist category for prostate cancer, with established commercial infrastructure.
  • Tolmar Pharmaceuticals: Specialty pharmaceutical company with Eligard (leuprolide) and supplying a long-acting injectable GnRH agonist in prostate cancer. Comparable to Medicus in the hormonal prostate cancer therapy space where Teverelix is positioning itself.

Broad incumbents

  • Sun Pharmaceutical Industries (Levulan/Kerastick): Large global pharmaceutical company with an approved photodynamic therapy (Levulan/kerastick) used in BCC treatment. Relevant comparable as an incumbent offering an established non-surgical BCC modality against which SkinJect would compete or pair.
  • PellePharm (a LEO Pharma company): Developed patidegib (a hedgehog pathway inhibitor) for Gorlin Syndrome under LEO Pharma. Most direct prior competitor in Gorlin Syndrome BCC treatment, providing historical context for the regulatory and clinical bar Medicus must clear with SkinJect.

Emerging players

  • Vaxxas: Clinical-stage company developing dissolvable microarray patch technology for vaccine and therapeutic delivery. Comparable to Medicus from a microneedle/drug-device delivery platform perspective (relevant to SkinJect D-MNA).
  • Aclaris Therapeutics: Clinical-stage dermatology therapeutics company developing novel topical and immuno-modulatory therapies for skin diseases including rare dermatologic indications. Comparable to Medicus as a small-cap clinical-stage dermatology biotech pursuing niche indications.
  • Krystal Biotech: Commercial-stage genetic medicines company that leveraged Orphan Drug and Rare Pediatric Disease Designations to commercialize Vyjuvek. Highly comparable as a small-cap biotech that successfully translated rare-disease designations into commercial value, illustrating the regulatory pathway Medicus is pursuing.

Others

  • Reliant AI Inc. AI-driven clinical data analytics platform partner co-developing Medicus's site selection, patient stratification, and enrollment forecasting capability. Relevant as the technology partner enabling Medicus's 'agentic AI-enabled drug development' narrative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Medicus Pharma social profiles

Digital presence

Medicus Pharma compliance and trust

Trust signal

Compliance4 records

Medicus Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medicus Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Medicus Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Medicus Pharma funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medicus Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicus Pharma

What does Medicus Pharma do?

Medicus Pharma is a precision-guided, clinical-stage biotech company that acquires and accelerates the development of novel therapeutic assets through Phase 2 proof-of-concept, then pursues licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization. Its pipeline includes SkinJect (a Doxorubicin Microneedle Array patch for basal cell carcinoma and Gorlin Syndrome) and Teverelix (a long-acting GnRH antagonist for advanced prostate cancer, acute urinary retention, and endometriosis).

Is Medicus Pharma a public or private company?

Medicus Pharma is a public company. It is classified as public and is currently operating.

When was Medicus Pharma founded?

Medicus Pharma was founded in 2023. It employs 11 to 50 people.

Where is Medicus Pharma based?

Medicus Pharma is headquartered in Toronto, Canada, in the North America region.

How does Medicus Pharma make money?

Two revenue lines are on record. Pre-revenue (clinical-stage) is the primary driver. The others are capital markets financing (non-operating).

Who are Medicus Pharma's main competitors?

Direct peers on record are Sol-Gel Technologies, Biofrontera Inc., Myovant Sciences (Sumitomo Pharma / Pfizer) and Tolmar Pharmaceuticals. Broad incumbents are Sun Pharmaceutical Industries (Levulan/Kerastick) and PellePharm (a LEO Pharma company). Emerging players are Vaxxas, Aclaris Therapeutics and Krystal Biotech. Reliant AI Inc. is listed as an others.

Does Medicus Pharma have an API?

No public API is recorded for Medicus Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Medicus Pharma Closes $4.25 Million Equity Financing And $10.5 Million Debt ExchangeMedicus Pharma closed $4.25 million in equity financings and exchanged $10.5 million in debt for preferred shares. The equity includes a $3 million registered direct offering and a $1.25 million private placement, priced at $1.72 per share. Proceeds will support working capital and development of its CD228V antibody-drug conjugate.Dealroom.coMedicus Pharma closes $4.25M CEO-led equity raise, swaps $10.5M in debt | Dealroom NewsMedicus Pharma closed $4.25 million in fixed-price equity financings led by CEO Raza Bokhari, and swapped $10.5 million in debt for preferred shares. The transactions push shareholders' equity above Nasdaq's $2.5 million continued-listing threshold, and the company is pivoting toward precision oncology with CD228V.The Motley FoolMedicus Pharma (MDCX) Q3 2026 Earnings Call TranscriptMedicus Pharma reported a Q3 2026 net loss of $15.2 million and a nine-month net loss of $35.9 million. The company announced a nonbinding letter of intent for a SkinJect SPAC combination at a $135 million pre-money valuation, with a projected closing in the first half of 2027. It also advanced a CD228V license with Pfizer and refined its Teverelix study to 126 patients.BenzingaMedicus Pharma Q3 2026 Earnings Call Transcript - Medicus Pharma (NASDAQ:MDCX)Medicus Pharma reported a net loss of $35.9 million for the first nine months of 2026, with operating expenses rising to $34.5 million. The company secured a co-development and license agreement with Pfizer for CD228V, and a proposed Skinjet business combination at $135 million pre-money is underway, targeting completion in the first half of 2027.American Banking and Market NewsMedicus Pharma (NASDAQ:MDCX) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Medicus Pharma from a sell to a strong sell rating. The stock opened at $1.87, with an average rating of Moderate Buy and a consensus price target of $450. The company reported a loss of $11.64 per share for the quarter, missing the consensus estimate.Stock TitanMedicus Pharma to Present CD228V at BIO-Europe 2026Medicus Pharma will present its oncology development focus at BIO-Europe 2026 on November 9 in Cologne, Germany. The presentation will highlight CD228V, an investigational antibody-drug conjugate, and SkinJect, a localized immuno-oncology product for Gorlin syndrome patients. The company will also cover the Teverelix program and partner outlook.TradingViewMedicus Pharma Proposes SkinJect SPAC Combination at $135 Million ValuationMedicus Pharma proposed combining SkinJect with an undisclosed SPAC, valuing SkinJect at $135 million before financing. The deal would create a separately listed SkinJect company, with Medicus retaining majority ownership, and is expected to close in the first half of 2027.TradingViewMedicus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or StandardNasdaq notified Medicus Pharma on October 23, 2026, that it regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), after closing bids remained at or above $1.00 for 10 consecutive business days from October 12 through October 23. Nasdaq closed the matter, superseding its October 20 delisting determination, and the company cautioned it may not maintain compliance with Nasdaq's listing requirements.American Banking and Market NewsMedicus Pharma (NASDAQ:MDCX) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Medicus Pharma to a strong sell rating on Saturday. The stock opened at $3.25, with an average rating of Moderate Buy and a consensus price target of $450.00. The company reported a loss of $10.50 per share for the quarter, missing the consensus estimate.MarketScreenerMedicus Pharma Ltd. Submits Optimized Seamless Phase 2B/3 Registration-Intent Protocol to FDA for Teverelix in Advanced Prostate CancerMedicus Pharma submitted an optimized seamless Phase 2b/3 registration-intent protocol to the FDA for Teverelix in advanced prostate cancer patients at increased cardiovascular risk. The design starts with about 80 randomized patients, then adds 528, totaling 608, and could reduce planned enrollment by about 60% compared to a 1,500-patient approach.